Allergan's Belkyra receives marketing authorisation in Sweden
Marketing authorization given for the treatment of moderate to severe fullness under the chin.
Allergan has announced that Sweden has received the marketing authorisation for Belkyra (deoxycholic acid) after being granted approval by the Swedish Medical Products Agency (MPA). Belkyra is a prescription medicine for the treatment of moderate-to-severe convexity or fullness associated with submental fat (often called double chin) in adults when the presence of submental fat has a psychological impact for the patient. Fullness under the chin can affect how a person feels about themselves and, for both women and men, can lead to feelings of negative self-impression.
"Belkyra provides physicians with one of the first clinically evaluated and approved treatments for their patients who are bothered by fullness under the chin. We are very excited to receive the marketing authorisation for Belkyra in Sweden and we are expecting more countries to follow in the next months," said Bill Meury, Chief Commercial Officer, Allergan. "We believe Belkyra will be a breakthrough treatment in Europe, as it has been in the US and Canada, and it complements our established medical aesthetics portfolio. We look forward to introducing Belkyra to other countries around Europe over the coming months, as we secure the additional national approvals."
Belkyra is the only non-surgical injectable treatment for reduction of fullness under the chin that has undergone rigorous clinical evaluation, including four Phase III clinical studies involving more than 2,600 patients worldwide. Until now, treatment options for submental fullness have been limited to surgical options such as liposuction and non-surgical in-clinic procedures using handheld devices or aggressive weight-loss regimens with potentially limited improvement. When injected into fat under the chin, Belkyra permanently causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat.
Treatment with Belkyra takes place in-clinic by a trained medical aesthetic physician. Many people experience improvement after two to four treatment sessions spaced at least 4 weeks apart. A maximum of six treatments may be given. A patient's physician will carry out a full facial assessment to help them determine how many treatment sessions they may need based on the amount and distribution of the fat under their chin and their personal treatment goals.
Four Phase III clinical studies have evaluated the efficacy and safety of Belkyra in adults with moderate-to-severe fullness under the chin; two in North America and two in Europe. In these studies, Belkyra was shown to have a high overall efficacy rate, demonstrated by a 1-grade improvement in fullness under the chin as assessed by the clinician in the study at 12 weeks after the last treatment (63.8% in European studies and 78.5% in the North American studies, respectively). Importantly, 44.6% of people treated with Belkyra in the European studies and 48.6% in the North American studies reported improvement in the psychological impact due to the fullness under their chin (compared with 18% and 17.3% of people treated with placebo, respectively) during the same time period. In the clinical studies, Belkyra was generally well tolerated. Most side effects (including injection site pain/swelling and bruising) were mild or moderate in severity, primarily associated with the treatment area and resolved without intervention.
As a next step, Allergan will begin to train appropriate healthcare professionals on the safe and effective use of this new treatment to ensure optimal patient satisfaction and outcomes.
Related News
-
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
News Eli Lilly's weight loss drugs removed from the FDA's shortage list
The US FDA have recently updated their drug shortage list. The recently released list shows that all dosage forms of Eli Lilly's weight-loss drug Zepbound and their diabetes drug Mounjaro are now available. -
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA).
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance